New studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant results in treating obesity and related 2 condition. Preclinical data suggest a novel mechanism contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/